Get App
Last Updated : May 16, 2018 06:55 PM IST | Source:

Buy Thyrocare Technologies; target of Rs 750: Edelweiss

Edelweiss is bullish on Thyrocare Technologies has recommended buy rating on the stock with a target price of Rs 750 in its research report dated May 03, 2018.

Broker Research @moneycontrolcom
  • bselive
  • nselive
Todays L/H

Edelweiss' research report on Thyrocare Technologies

In Q4FY18, Thyrocare posted lowest top-line growth—11%—since IPO. This was due to the first-ever decline in Wellness, led by heightened competition, which we have been highlighting for the past six quarters. Despite Q4 being a seasonally strong quarter, rising share of regional PE-backed players, especially in Delhi, coupled with non-recurrence of promotional activity, led to the deceleration. EBITDA margin also fell to 38% from past three quarters’ run rate of 42%. The blip has prompted the company to undertake following changes in strategy: i) shift focus back to B2B; ii) spend 5% of sales on advertising; and iii) promote franchise model in imaging. Given the current macros, we believe successful implementation of this strategy is key.


Though we believe achieving the 25% FY19 revenue growth guidance will be challenging (our estimate 18%), we will wait and watch if the new strategy is successful on a favourable base. Maintain ‘BUY’ with TP of INR750.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Moneycontrol Ready Reckoner
Now that payment deadlines have been relaxed due to COVID-19, the Moneycontrol Ready Reckoner will help keep your date with insurance premiums, tax-saving investments and EMIs, among others.

First Published on May 16, 2018 06:55 pm
Follow us on